No retraction, correction or concern found when last checked on Oct 31, 2026.

Treatment-resistant depression and peripheral C-reactive protein

Samuel R. Chamberlain, Jonathan Cavanagh, Peter de Boer and 8 more

British Journal of Psychiatry · 2018

doi:10.1192/bjp.2018.66

Abstract

Background. C-reactive protein (CRP) is a candidate biomarker for major depressive disorder (MDD), but it is unclear how peripheral CRP levels relate to the heterogeneous clinical phenotypes of the disorder.

Aim. To explore CRP in MDD and its phenotypic associations.

Method. We recruited 102 treatment-resistant patients with MDD currently experiencing depression, 48 treatment-responsive patients with MDD not currently experiencing depression, 48 patients with depression who were not receiving medication and 54 healthy volunteers. High-sensitivity CRP in peripheral venous blood, body mass index (BMI) and questionnaire assessments of depression, anxiety and childhood trauma were measured. Group differences in CRP were estimated, and partial least squares (PLS) analysis explored the relationships between CRP and specific clinical phenotypes.

Results. Compared with healthy volunteers, BMI-corrected CRP was significantly elevated in the treatment-resistant group (P = 0.007; Cohen's d = 0.47); but not significantly so in the treatment-responsive (d = 0.29) and untreated (d = 0.18) groups. PLS yielded an optimal two-factor solution that accounted for 34.7% of variation in clinical measures and for 36.0% of variation in CRP. Clinical phenotypes most strongly associated with CRP and heavily weighted on the first PLS component were vegetative depressive symptoms, BMI, state anxiety and feeling unloved as a child or wishing for a different childhood.

Conclusions. CRP was elevated in patients with MDD, and more so in treatment-resistant patients. Other phenotypes associated with elevated CRP included childhood adversity and specific depressive and anxious symptoms. We suggest that patients with MDD stratified for proinflammatory biomarkers, like CRP, have a distinctive clinical profile that might be responsive to second-line treatment with anti-inflammatory drugs.

Declaration of interest. S.R.C. consults for Cambridge Cognition and Shire; and his input in this project was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z). E.T.B. is employed half time by the University of Cambridge and half time by GlaxoSmithKline; he holds stock in GlaxoSmithKline. In the past 3 years, P.J.C. has served on an advisory board for Lundbeck. N.A.H. consults for GlaxoSmithKline. P.d.B., D.N.C.J. and W.C.D. are employees of Janssen Research & Development, LLC., of Johnson & Johnson, and hold stock in Johnson & Johnson. The other authors report no financial disclosures or potential conflicts of interest.

References 65

1.
Bhattacharya A, Derecki NC, Lovenberg TW, Drevets WC. Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology (Berl) 2016; 233(9): 1623–36.
Not in our library10.1007/s00213-016-4214-0
2.
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9(1): 46–56.
Not in our library10.1038/nrn2297
3.
Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 2015; 25(10): 1532–43.
Not in our library10.1016/j.euroneuro.2015.06.007
4.
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34(4): 301–9.
Not in our library10.1016/0165-0327(95)00028-l
5.
Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27(1): 24–31.
Not in our library10.1016/j.it.2005.11.006
6.
Frasure-Smith N, Lesperance F, Irwin MR, Sauve C, Lesperance J, Theroux P. Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Biol Psychiatry 2007; 62(4): 302–8.
Not in our library10.1016/j.biopsych.2006.09.029
7.
Kinney DK, Tanaka M. An evolutionary hypothesis of depression and its symptoms, adaptive value, and risk factors. J Nerv Ment Dis 2009; 197(8): 561–7.
Not in our library10.1097/nmd.0b013e3181b05fa8
8.
Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder · 2015
No notice
9.
Young JJ, Silber T, Bruno D, Galatzer-Levy IR, Pomara N, Marmar CR. Is there progress? An overview of selecting biomarker candidates for major depressive disorder. Front Psychiatry 2016; 7: 72.
Not in our library10.3389/fpsyt.2016.00072
10.
Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections · 2010
No notice
11.
Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry 2003; 60(10): 1009–14.
Not in our library10.1001/archpsyc.60.10.1009
12.
Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 2013; 38(3): 377–85.
Not in our library10.1038/npp.2012.191
13.
Cattaneo A, Ferrari C, Uher R, Bocchio-Chiavetto L, Riva MA, Consortium MRCI, Absolute measurements of macrophage migration inhibitory factor and interleukin-1-beta mRNA levels accurately predict treatment response in depressed patients. Int J Neuropsychopharmacol 2016; 19(10): pyw045.
Not in our library10.1093/ijnp/pyw045
14.
Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25(3): 201–15.
Not in our library10.1002/hup.1103
15.
Replicable and Coupled Changes in Innate and Adaptive Immune Gene Expression in Two Case-Control Studies of Blood Microarrays in Major Depressive Disorder · 2018
No notice
16.
Hickman RJ, Khambaty T, Stewart JC. C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination survey (NHANES) 1999-2004. J Behav Med 2014; 37(4): 621–9.
Not in our library10.1007/s10865-013-9510-0
17.
Miller GE, Cole SW. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry 2012; 72(1): 34–40.
Not in our library10.1016/j.biopsych.2012.02.034
18.
Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ. Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis. Biol Psychiatry 2012; 71(1): 15–21.
Not in our library10.1016/j.biopsych.2011.09.023
19.
Liukkonen T, Rasanen P, Jokelainen J, Leinonen M, Jarvelin MR, Meyer-Rochow VB, The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 birth cohort study. Eur Psychiatry 2011; 26(6): 363–9.
Not in our library10.1016/j.eurpsy.2011.02.001
20.
Abdi H, Williams LJ. Partial least squares methods: partial least squares correlation and partial least square regression. Methods Mol Biol 2013; 930: 549–79.
Not in our library10.1007/978-1-62703-059-5_23
21.
Wold H. Estimation of Principal Components and Related Models by Iterative Least Squares. Academic Press, 1966.
Not in our library
22.
Wold S. Personal memories of the early PLS development. Chemometrcs Intell Lab Syst 2001; 58: 83–4.
Not in our library
23.
Menzies L, Achard S, Chamberlain SR, Fineberg N, Chen CH, del Campo N, Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 2007; 130(Pt 12): 3223–36.
Not in our library10.1093/brain/awm205
24.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). American Psychiatric Publishing, 2013.
Not in our library
25.
Spitzer MB, Miriam G, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID). American Psychiatric Press, Inc., 1996.
Not in our library
26.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
Not in our library10.1136/jnnp.23.1.56
27.
Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. J Clin Psychiatry 2011; 72(8): 1152–4.
Not in our library10.4088/jcp.11ac07225
28.
Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28(2): 156–65.
Not in our library10.1097/jcp.0b013e31816774f9
29.
Katona CL, Robertson MM, Abou-Saleh MT, Nairac BL, Edwards DR, Lock T, Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Int Clin Psychopharmacol 1993; 8(4): 323.
Not in our library10.1097/00004850-199300840-00020
30.
Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory - II. Psychological Corporation, 1996.
Not in our library
31.
Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, 1983.
Not in our library
32.
Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Development of a fatigue scale. J Psychosom Res 1993; 37(2): 147–53.
Not in our library10.1016/0022-3999(93)90081-p
33.
Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167(1): 99–103.
Not in our library10.1192/bjp.167.1.99
34.
Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 1994; 151(8): 1132–6.
Not in our library10.1176/ajp.151.8.1132
35.
Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29(8): 439–93.
Not in our library
36.
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70(1): 31–41.
Not in our library10.1001/2013.jamapsychiatry.4
37.
JMP Pro ® Version 13.0, Cary, North Carolina, USA. SAS Institute Inc., 2017.
Not in our library
38.
Garthwaite PH. An interpretation of partial least squares. J Am Stat Assoc 1994; 89(425): 122–7.
Not in our library
39.
Höskuldsson A. PLS regression methods. J Chemometrics 1988; 2(3): 211–28.
Not in our library
40.
Cox I, Gaudard M. Discovering Partial Least Squares with JMP. SAS Institute Inc., 2013.
Not in our library
41.
Terpening WD. Statistical Analysis for Business Using JMP: A Student's Guide. SAS Institute Inc., 2011.
Not in our library
42.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107(3): 391–7.
Not in our library10.1161/01.cir.0000055014.62083.05
43.
Zhao Y, Lv G. Correlation of C-reactive protein level and obesity in Chinese adults and children: a meta-analysis. J Endocrinol Invest 2013; 36(8): 642–7.
Not in our library10.3275/9004
44.
Janka Z. Serotonin dysfunctions in the background of the seven deadly sins. Ideggyogy Sz 2003; 56(11–12): 376–85.
Not in our library
45.
Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012; 6: 369–88.
Not in our library10.2147/ppa.s29716
46.
Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, European Group for the Study of Resistant Depression (GSRD) – where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 2012; 22(7): 453–68.
Not in our library10.1016/j.euroneuro.2012.02.006
47.
Lepine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011; 7(suppl 1): 3–7.
Not in our library10.2147/ndt.s19617
48.
Bhattacharya A, Drevets WC. Role of neuro-immunological factors in the pathophysiology of mood disorders: implications for novel therapeutics for treatment resistant depression. Curr Top Behav Neurosci 2017; 31: 339–56.
Not in our library10.1007/7854_2016_43
49.
Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord 2013; 148(1): 136–40.
Not in our library10.1016/j.jad.2012.10.036
50.
Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 2017; 78: 105–13.
Not in our library10.1016/j.psyneuen.2017.01.023
51.
Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 2014; 171(12): 1278–86.
Not in our library10.1176/appi.ajp.2014.14010094
52.
Walker AJ, Foley BM, Sutor SL, McGillivray JA, Frye MA, Tye SJ. Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. Behav Brain Res 2015; 293: 198–202.
Not in our library10.1016/j.bbr.2015.07.026
53.
Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10(6): 538–44.
Not in our library10.1038/sj.mp.4001600
54.
Neuropathology of mood disorders: do we see the stigmata of inflammation? · 2016
No notice
55.
Postal M, Appenzeller S. The importance of cytokines and autoantibodies in depression. Autoimmun Rev 2015; 14(1): 30–5.
Not in our library10.1016/j.autrev.2014.09.001
56.
Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012; 37(1): 137–62.
Not in our library10.1038/npp.2011.205
57.
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96(9): 939–49.
Not in our library10.1161/01.res.0000163635.62927.34
58.
Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ, Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry 2008; 64(10): 896–900.
Not in our library10.1016/j.biopsych.2008.05.019
59.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82(12): 4196–200.
Not in our library10.1210/jcem.82.12.4450
60.
Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BW. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 2013; 38(9): 1573–85.
Not in our library10.1016/j.psyneuen.2013.01.002
61.
Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26(5): 643–52.
Not in our library10.1016/s0893-133x(01)00407-9
62.
Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58(5): 445–52.
Not in our library10.1001/archpsyc.58.5.445
63.
Sachs-Ericsson N, Kendall-Tackett K, Hernandez A. Childhood abuse, chronic pain, and depression in the National Comorbidity Survey. Child Abuse Negl 2007; 31(5): 531–47.
Not in our library10.1016/j.chiabu.2006.12.007
64.
Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α · 2015
No notice
65.
Lu S, Peng H, Wang L, Vasish S, Zhang Y, Gao W, Elevated specific peripheral cytokines found in major depressive disorder patients with childhood trauma exposure: a cytokine antibody array analysis. Compr Psychiatry 2013; 54(7): 953–61.
Not in our library10.1016/j.comppsych.2013.03.026

Cited by papers we hold 17

Nutraceutical eicosapentaenoic acid in treatment-resistant depression: The psychoneuroimmunity and clinical implications · 2025
Not checked
Immunoregulatory role of the gut microbiota in inflammatory depression · 2024
No notice
Biological factors influencing depression in later life: role of aging processes and treatment implications · 2023
No notice
Molecular pathways of major depressive disorder converge on the synapse · 2022
No notice
C-Reactive Protein as a Biomarker for Major Depressive Disorder? · 2022
No notice
Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis · 2022
No notice
Effects of Subtypes of Child Maltreatment on CRP in Adulthood · 2021
Not checked
Treatment resistance in psychiatry: state of the art and new directions · 2021
No notice
Comparison of psychiatric symptoms between patients with major depression with higher and lower levels of high-sensitivity C-reactive protein in the serum: a preliminary study · 2021
Not checked
Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis · 2021
No notice
Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls · 2020
No notice
Peripheral Markers of Depression · 2020
No notice
Psychiatric face of COVID-19 · 2020
No notice
Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism · 2019
Not checked
Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels · 2019
No notice
Age-Associated Changes in the Immune System and Blood–Brain Barrier Functions · 2019
No notice
Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort · 2019
Corrected

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.